Cardiovascular, Renal, and Metabolic Diseases

Airfinity specialises in delivering innovative, tailor-made solutions that transcend traditional industry offerings, catering to the unique needs of cardiovascular, renal, and metabolic healthcare sectors and helping key decision makers to look forward not back.

Disease Analytics & Forecasting for Improved Health Outcomes

Airfinity works across the entire cardiovascular, renal, and metabolic landscape and has developed a comprehensive suite of world-leading predictive solutions and capabilities, using structured time series data sets and advanced analytics to support the lifescience industry​.

We overlay extensive data analysis over historical models to provide independent insights and recommendations. Real-time, data-driven solutions support medical and commercial teams in making informed decisions that improve patient outcomes and commercial success. Subject matter experts analyse, commentate and contextualise all our data through platform insights, custom reports and regular in-person briefings.

Pipeline Surveillance and Predictions

Get a 360 degree view on all candidates from pre-clinical research stage through to post-approval in one place – where all data is interactive, filterable, structured, and updated in real time to support R&D and commercial strategies.

Standard of Care Forecasting

Combining Airfinity’s scenario-based forecast models with clinical trials data, guideline data, approvals data, pipeline tracking, financial reports, conference presentations, and KOL opinions to identify opportunities and threats to your drug’s clinical programme, and determine when and where novel candidates would fit into patient standard-of-care.

KOL Mapping

Global analysis to identify and rank healthcare professionals and key opinion leaders within your defined therapy area. Prioritise KOL’s for engagement prior to regulatory approval submissions and guideline decisions, in order to make the drug approval process smoother and potentially increase prescriptions post approval.

Conference Reports

Post-conference analysis of flagship events, including ACC, AHA, ESC, etc, that outline key data shared and the implications for the industry. The reports include sentiment and H-Index analysis, as well as tailored deep dives for your chosen drug class or indication.

Research Power Index and Scientific Share of Voice (SSoV)

Global analysis to identify and rank countries, research organisations, and funding agencies within a therapy area. Benchmark your own scientific output, and identify and prioritise research organisations for investment & partnerships.

Custom Analytics

Our experts can provide bespoke analyst support and consulting services to help answer your key questions with custom analytics. We can go beyond our standard offerings to deliver tailor-made solutions to suit your specific needs.

Coverage

Dyslipidemia | Hypertension | Cardiovascular Inflammation | Atherosclerosis | Thrombotic disorders | Heart Failure | Transthyretin Amyloidosis | Obesity | Diabetes | Chronic Kidney Disease

Analysis & Insights

Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death
Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death

Airfinity has revised its cost effectiveness analysis for Wegovy, increasing the cost of preventing one heart attack, stroke or cardio vascular death from $1.1m to $1.3m.

Read More →


More from Airfinity

Anti-obesity drug rush: Industry 'testing' nearly 190 candidates (es)

Sixty seconds on . . . the cost of semaglutide

Weight loss injections could prevent 300,000 heart failures in the US by 2030, forecasts Airfinity

Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.

View All →

Request Information

Get in touch to learn more about Airfinity’s cardiovascular, renal and metabolic solutions.